

TRANSFORMING TREATMENT IN HR+/HER2- ADVANCED BREAST CANCER

Available On-Demand Beginning September 22, 2020, 09:00 CET

AGENDA

Welcome and Introduction

Evolution of Approved Targeted Therapies in HR+/HER2- ABC

A Breakthrough: Overall Survival Results with CDK4/6 Inhibitors in HR+/HER2- ABC

New Avenues: Expanding the Evidence Base with P13K Inhibitors

Closing Remarks



Michele De Laurentiis, MD, PhD

Chair, Department of Breast and
Thoracic Oncology National Cancer Institute
"Fondazione Pascale"
Naples, Italy



Hope S. Rugo, MD, FASCO

Professor of Medicine Director, Breast Oncology
and Clinical Trials Education UCSF
Helen Diller Family Comprehensive Cancer Ctr
San Francisco, CA

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.
This program and/or material was developed for use outside of the US, intended for non-US HCPs, and is to be used in accordance with local laws and regulations.